# PTPRT

Source: https://onco.cc/targets/ptprt/  
OnCo record `ptprt` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.

## Summary

May be involved in both signal transduction and cellular adhesion in the CNS.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming JSI-124 and Stattic. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.94, animal model 0.62, genetic association 0.32, somatic mutation 0.90). IntOGen calls it a driver in 8 cohorts (7 activating, 1 loss-of-function), covering Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Ovarian Epithelial Tumour, Pancreatic Adenocarcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: protein tyrosine phosphatase receptor type T; Receptor-type tyrosine-protein phosphatase T; RPTPrho; KIAA0283
- Tags: cancer-genes-wave
- Symbol: PTPRT
- Class: enzyme
- Biology: May be involved in both signal transduction and cellular adhesion in the CNS. Location: Membrane (UniProt). Locus 20q12-q13.11 (HGNC).
- Where found: Head and neck squamous cell carcinoma: CIViC evidence names this disease; IntOGen driver in 1 cohort (HNSC); Oesophageal cancer: Open Targets association 0.54 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA); Gastric & gastro-oesophageal junction cancer: Open Targets association 0.54 with gastric cancer (MONDO_0001056); IntOGen driver in 1 cohort (STAD); Ovarian cancer: Open Targets association 0.50 with ovarian cancer (MONDO_0008170); IntOGen driver in 1 cohort (OVT); Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 7 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9682: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9682
- UniProt O14522: https://www.uniprot.org/uniprotkb/O14522/entry
- NCBI Gene 11122: https://www.ncbi.nlm.nih.gov/gene/11122
- Ensembl ENSG00000196090: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196090

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/ptprt.json